One possible explanation is that in patients with VHL‐WT, SERPINH1 exerts its EMT‐enhancing function, followed by promoting ccRCC progression; in patients with VHL‐MT, however, VHL mutation‐mediated hypoxia‐inducible factor 1α (HIF1α) accumulation and TGFβ signalling activation exert a prominent function over SERPINH1. This evidence concerns the gene HIF1A and nonpapillary renal cell carcinoma.